SEC Form 4 · accession 0001209191-16-147712
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark G Currie
Officer — Chief Scientific Officer
Period of report
Oct 31, 2016
Accepted (ET)
Nov 1, 2016 · 6:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class B Common StockF1 | Oct 31, 2016 | M | 300,000 | $2.94 | A | 685,000 | D | |
| Class A Common Stock | holding | — | — | — | 25,558 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $2.94 | Oct 31, 2016 | M | 300,000 | D | — | Jan 22, 2017 | Class B Common Stock | 300,000 | 0 | D |
Explanation of responses
- F1The right to acquire the shares will vest upon the earlier of (i) the Issuer's achievement of certain clinical, regulatory and market capitalization milestones and (ii) January 22, 2017.
- F2On October 31, 2016, the reporting person exercised the option pursuant to an early exercise provision. The right to acquire the shares will vest upon the earlier of (i) the Issuer's achievement of certain clinical, regulatory and market capitalization milestones and (ii) January 22, 2017.